Vertex, Inc. VERX
17.23 USD +0.05 (+0.29%)
Regular-session close
17.23 0.00 0.00%
After hours · Nov 20, 4:26 PM ET
16.88 Day range 17.70
10.21 52-week range 20.82
- YTD
- -13.72%
- 1 year
- -11.78%
News
seekingalpha.com Vertex Pharmaceuticals: Look For Povetacicept Approval In 2 Weeks As Next Catalyst Vertex Pharmaceuticals Incorporated remains a Buy: shares look fairly valued, but durable CF cash flows and pipeline potential support long-term market outperformance. VRTX's CF franchise accounts…
fool.com Johnson & Johnson vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027? Johnson & Johnson offers a diversified healthcare portfolio and massive scale across its MedTech and pharmaceutical segments. Vertex Pharmaceuticals maintains a dominant position in the cystic…
marketbeat.com Vertex Pharmaceuticals Eyes Nov. 30 Kidney Drug Decision as 2027 Pipeline Milestones Loom Vertex Pharmaceuticals NASDAQ: VRTX is approaching a Nov. 30 U.S. regulatory decision for its kidney disease drug povetacicept, with a series of clinical readouts expected through 2027 as the company…
globenewswire.com Vertex Survey: Inaccurate Checkout Totals Are the Top Trust Breaker for 2026 Holiday Shoppers KING OF PRUSSIA, Pa., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), the Decision-to-Defense™ global indirect tax and compliance company, today released new…
marketbeat.com Vertex Pharmaceuticals Prepares for Key Kidney Drug Decision as Pipeline Readouts Loom Vertex Pharmaceuticals NASDAQ: VRTX is preparing for a Nov. 30 U.S. regulatory decision on its kidney disease treatment povetacicept, while awaiting clinical results across kidney disease, chronic…
seekingalpha.com Maze Therapeutics: Vertex Is Building The Road, And Maze Gets To Drive On It Maze Therapeutics, Inc. is positioned as the only APOL1 inhibitor competitor to Vertex, with strong Phase 2 data and funding into 2029. MAZE's HORIZON trial showed robust uACR reductions, especially…
benzinga.com Motorola Solutions, Sezzle, Unity Software, Toyota Motor And Other Big Stocks Moving Higher On Thursday U.S. stocks were mixed as Nasdaq fell over 3%, while Motorola Solutions and other companies surged on strong earnings and raised guidance.
benzinga.com Vertex Analysts Boost Their Forecasts After Better-Than-Expected Q3 Results Vertex beats Q3 estimates, raises FY26 sales guidance, and shares jump 15%; analysts lift price targets to $20-$30.benzinga.com Needham Maintains Buy on Vertex, Raises Price Target to $30 Needham analyst Joshua Reilly maintains Vertex (NASDAQ:VERX) with a Buy and raises the price target from $20 to $30.
benzinga.com 12 Information Technology Stocks Moving In Thursday's Pre-Market Session Gainers Unity Software (NYSE:U) stock increased by 22.2% to $51.9 during Thursday's pre-market session. The company's market cap stands at $18.5 billion. As per the news, the Q3 earnings report came…benzinga.com Piper Sandler Maintains Neutral on Vertex, Raises Price Target to $20 Piper Sandler analyst Billy Fitzsimmons maintains Vertex (NASDAQ:VERX) with a Neutral and raises the price target from $16 to $20.
benzinga.com Vertex Raises FY2026 Sales Guidance from $825.000M-$830.000M to $828.900M-$830.900M vs $827.231M Est Vertex (NASDAQ:VERX) raises FY2026 sales outlook from $825.000 million-$830.000 million to $828.900 million-$830.900 million vs $827.231 million estimate.
benzinga.com Asure Software And Vertex Partner To Deliver Improved Payroll Tax Calculation And Compliance Offering To US Enterprise Market Asure Software, Inc. (NASDAQ:ASUR), a leading provider of cloud-based Human Capital Management software and payroll tax management solutions, and Vertex, Inc. (NASDAQ:VERX), the Decision-to-Defense™…
benzinga.com Vertex Launches Vertex Sol Vertex, Inc. (NASDAQ:VERX) ("Vertex" or the "Company"), the Decision-to-Defense™ global indirect tax and compliance company, today introduced Vertex Sōl™, a connected compliance experience that brings
